Daily Cardiology Research Analysis
Analyzed 99 papers and selected 3 impactful papers.
Summary
Three high-impact studies span device innovation, comparative effectiveness, and inflammation-resolution biology. A Nature Biomedical Engineering study demonstrates a self-powering transcatheter pacemaker that harvests cardiac motion to surpass energy needs in a porcine model. A nationwide target-trial emulation shows SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury compared with GLP-1 receptor agonists in type 2 diabetes, and a translational study reveals Maresin 1 enhances cardiac resident macrophage efferocytosis to limit myocardial ischemia–reperfusion injury via PPARγ signaling.
Research Themes
- Energy-harvesting cardiac devices and lifelong pacing
- Comparative effectiveness of antidiabetic agents for cardiorenal protection
- Inflammation-resolution mediators and macrophage efferocytosis in myocardial injury
Selected Articles
1. Symbiotic transcatheter pacemaker for lifelong energy regeneration and therapeutic function in porcine disease model.
This study demonstrates a miniaturized, hemocompatible transcatheter pacemaker that harvests energy from cardiac motion using electromagnetic induction and a magnetic levitation cache, surpassing the energy threshold for lifelong pacing. In a porcine bradyarrhythmia model, the device operated autonomously for one month while providing therapeutic pacing, pointing to a viable path toward battery-independent cardiac pacing.
Impact: It introduces a paradigm-shifting approach to lifelong pacing by eliminating battery replacement through in situ energy harvesting, validated in a large-animal model.
Clinical Implications: If translated to humans, this technology could reduce generator replacements, infection risk, and cumulative lead-related procedures by enabling battery-independent pacing delivered via a transcatheter approach.
Key Findings
- Electromagnetic energy harvesting with a magnetic levitation energy cache surpassed the critical energy condition for lifelong pacing.
- The device showed favorable biocompatibility and hemocompatibility and is amenable to interventional delivery.
- In a porcine bradyarrhythmia model, month-long autonomous operation with therapeutic pacing was achieved.
Methodological Strengths
- Large-animal (porcine) validation with month-long autonomous operation
- Engineering innovation minimizing mechanical losses via magnetic levitation energy cache and demonstrating hemocompatibility
Limitations
- Preclinical study without human implantation or long-term (>1 month) durability data
- Energy harvesting and pacing performance under diverse human physiological conditions remain untested
Future Directions: First-in-human feasibility, chronic durability testing, thromboembolic safety, and integration with contemporary leadless or modular systems to enable clinical translation.
Lifelong pacing is one of the ultimate goals of cardiac pacemakers. However, meeting the critical energy condition for lifelong service is a tremendous challenge. Here we report a symbiotic transcatheter pacemaker that regenerates electric energy from heart motion via electromagnetic induction and surpasses the critical energy condition for lifelong service. The pacemaker can be closely integrated with the body owing to favourable biocompatibility and hemocompatibility, and its small size enables interventional delivery. To minimize energy loss and eliminate mechanical collision and friction, we propose a straightforward magnetic levitation energy cache structure. The energy regeneration module has a near-zero boot threshold, high kinetic energy conversion efficiency and intracardiac root mean square output power. We show the energy regeneration and therapeutic function of the symbiotic transcatheter pacemaker over a month-long autonomous operation in a porcine model of brady-arrhythmia. These advances may provide a potential path to extend the service life of pacemakers to the level of the natural heart.
2. SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes.
In a nationwide target trial emulation including 36,279 SGLT2i and 18,782 GLP-1RA initiators, SGLT2i use was associated with lower 5-year risk of chronic kidney disease (risk ratio 0.81; risk difference −1.5%) and fewer acute kidney injury events (MCC ratio 0.88). Albuminuria and mortality were slightly reduced with GLP-1RA. Benefits of SGLT2i were most pronounced in those without preexisting kidney disease.
Impact: This large-scale, methodologically rigorous emulation addresses a key evidence gap by directly comparing two cardio-renal protective classes, informing drug selection when head-to-head RCTs are lacking.
Clinical Implications: For metformin-treated type 2 diabetes, initiating SGLT2 inhibitors favors primary prevention of CKD and reduces AKI burden versus GLP-1RA; GLP-1RA may be preferred when albuminuria reduction or weight loss predominates. Personalization should consider baseline kidney status and comorbidities.
Key Findings
- Weighted 5-year CKD risk: 6.7% with SGLT2i vs 8.2% with GLP-1RA (risk ratio 0.81; risk difference −1.5%).
- 5-year AKI mean cumulative counts per 100 individuals: 25.2 with SGLT2i vs 28.7 with GLP-1RA (ratio 0.88).
- Albuminuria and mortality were slightly reduced with GLP-1RA; SGLT2i effects on CKD and AKI were strongest in those without preexisting kidney disease.
Methodological Strengths
- Target trial emulation with inverse probability of treatment weighting and Aalen–Johansen estimator for competing risks
- Nationwide, population-based cohort with long follow-up and prespecified subgroup analyses
Limitations
- Observational design subject to residual confounding and treatment channeling
- Medication adherence, dosing nuances, and lifestyle factors are imperfectly captured in registries
Future Directions: Head-to-head randomized trials and pragmatic trials in diverse health systems; mechanistic studies dissecting differing effects on albuminuria and mortality; decision-analytic models integrating cardio-renal and metabolic outcomes.
IMPORTANCE: No randomized clinical trial has directly compared the effectiveness of sodium-glucose cotransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in reducing acute and chronic kidney outcomes. OBJECTIVE: To examine the comparative effectiveness of SGLT2i and GLP-1RA treatment for acute and chronic kidney outcomes in individuals with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study with a target trial emulation design used nationwide, population-based data from Denmark. Participants were individuals with metformin-treated type 2 diabetes who initiated SGLT2i or GLP-1RA treatment from January 2014 to November 2020, with follow-up through October 2024. EXPOSURE: Initiation of an SGLT2i or a GLP-1RA. MAIN OUTCOMES AND MEASURES: The 2 coprimary outcomes were chronic kidney disease (CKD; 40% reduction in estimated glomerular filtration rate [eGFR], severe albuminuria, or kidney failure) and acute kidney injury (AKI). Secondary outcomes included the individual components of CKD, albuminuria, and death. Intention-to-treat effects were estimated using inverse probability of treatment weights, comparing risks for CKD assessed by the Aalen-Johansen estimator, and AKI burden by mean cumulative counts (MCCs; mean number of events per individual as multiple AKI events were possible). Subgroup analyses included stratification by preexisting cardiovascular or kidney disease.
3. Maresin 1 ameliorates myocardial ischemia‒reperfusion injury by promoting tissue resident macrophage efferocytosis.
Maresin 1 (MaR1) was inversely associated with inflammation and I/R injury severity in STEMI patients and improved function after experimental I/R by enhancing resident macrophage efferocytosis. Mechanistically, MaR1 directly bound PPARγ, upregulated CD204, and boosted fatty acid β-oxidation in cardiac RMs; RM ablation or PPARγ knockout abrogated benefits, and DHA supplementation recapitulated protection.
Impact: It connects a specialized pro-resolving mediator to macrophage efferocytosis and identifies a druggable PPARγ–CD204 axis for limiting reperfusion injury, with translational signals from human data and dietary precursor reproducibility.
Clinical Implications: MaR1 or strategies augmenting PPARγ-dependent efferocytosis (e.g., DHA supplementation) could complement current AMI care to mitigate I/R injury. Biomarker-guided enrichment using circulating MaR1 may aid trial design.
Key Findings
- Circulating MaR1 inversely correlated with inflammatory markers and I/R injury severity in STEMI patients.
- MaR1 improved cardiac function post-I/R by enhancing resident macrophage efferocytosis; ablation of RMs eliminated protection.
- Mechanism: direct PPARγ binding, upregulation of CD204, and increased FA β-oxidation in RMs; PPARγ knockout attenuated effects; DHA recapitulated cardioprotection.
Methodological Strengths
- Integrated human clinical association with multi-omics mechanistic validation in vivo
- Genetic and cellular specificity: resident macrophage depletion and PPARγ knockout establish causality
Limitations
- Human data are associative and from a case–control design; interventional human trials are lacking
- Preclinical timing/dosing and translatability to standard AMI workflows remain to be established
Future Directions: Phase 1/2 trials of MaR1 or DHA-enriched strategies in STEMI with biomarker stratification; exploration of synergy with reperfusion timing and adjunctive anti-inflammatory therapies.
AIMS: Myocardial ischemia‒reperfusion (I/R) injury triggers a robust inflammatory storm cascade that critically compromises reperfusion efficacy following acute myocardial infarction (AMI). Enhanced efferocytosis by cardiac resident macrophages (RMs) has therapeutic potential for inflammation resolution. The unsaturated long‒chain fatty acid Maresin1 (MaR1) exhibits potent anti‒inflammatory properties that is devoid of immunosuppressive effects. However, its therapeutic potential in myocardial I/R injury and regulatory mechanisms in cardiac RMs remains unexplored. METHODS AND RESULTS: A clinical case‒control study was conducted and revealed a negative association between circulating MaR1 levels and inflammatory markers and the severity of I/R injury in patients with ST‒elevation myocardial infarction (STEMI). Mice treated with MaR1 after myocardial I/R injury showed improvements in cardiac function and efferocytosis by cardiac RMs. Genetic ablation of cardiac RMs abolished MaR1‒mediated cardioprotection. To explore the mechanism underlying this protection, we performed transcriptomic, metabolomic and lipidomic analyses and identified fatty acid β‒oxidation potentiation as a key metabolic signature in MaR1‒treated RMs. Morever, MaR1 directly bound peroxisome proliferator‒activated receptor γ (PPARγ), inducing the transcriptional activation of its downstream efferocytosis‒related target CD204. Specific knockout of PPARγ in RMs significantly attenuated MaR1‒enhanced efferocytosis. Notably, oral supplementation with the MaR1 precursor docosahexaenoic acid (DHA) recapitulated these cardioprotective effects. CONCLUSIONS: Our findings prove that MaR1 plays a protective role in myocardial I/R injury by facilitating efferocytosis by RMs and the resolution of inflammation. These results offer novel therapeutic perspectives for the management of myocardial I/R injury.